Emboline, Inc. to Debut Game-Changing Embolic Protection Technology for Percutaneous Heart Valve Procedures in San Francisco Next Week
Embolines technologies are derived from intellectual property invented by Amir Belson, M.D., founder of Neoguide Systems, a company that developed platform technology for minimally invasive surgical procedures and was acquired by Intuitive Surgical in 2009.
Emboline is working toward an acute preclinical proof-of-concept of its technology, targeted by Q1 2012. The proof-of-concept development is being done in partnership with NDC (Fremont, Calif.), SeptRx, Inc. (Fremont, Calif.) and US BioDesign (Perkasie, Penn.).
"The major focus on transcatheter aortic valve replacement at next weeks TCT 2011 conference in San Francisco is strong evidence of the important need for our technology," said Scott Russell, Embolines General Manager. "For these exciting new TAVR procedures to reach their true potential, the stroke risk must be properly managed. Our technology not only eliminates the risk of embolic stroke from these procedures, but it is also the only technology to simultaneously shield the aortic lumen to protect the rest of the arterial bed as well."
Cerebral embolism is a known complication of cardiac surgery, cardiopulmonary bypass and catheter based interventional cardiology and electrophysiology procedures. Embolic particles, which may include thrombus, atheroma and lipids, may become dislodged by surgical or catheter manipulations and enter the bloodstream. Cerebral embolism can lead to neuropsychological deficits, stroke and even death. Other organs downstream can also be damaged by embolism, resulting in diminished function or organ failure. Prevention of such embolism would benefit patients and improve the outcome of these procedures. These risks are especially critical in transcatheter aortic valve replacement (TAVR). Stroke rates related to TAVR have been recorded at between four and 20 percent. During catheter delivery and valve implantation, plaque may be dislodged from the vasculature and may travel through the carotid circulation and into the brain. The adoption and growth of TAVR procedures may be stifled until a reliable, simple-to-use embolic protection system exists to improve the safety of these procedures.
For further information about Embolines technologies, please contact Scott Russell (General Manager) at firstname.lastname@example.org, 510/225–9258, x1.